Literature DB >> 29172123

Existing and emerging therapies for managing constipation and diarrhea.

Adil E Bharucha1, Mira M Wouters2, Jan Tack2.   

Abstract

Functional bowel disorders (i.e., constipation and diarrhea) are characterized by abdominal pain, bloating, distention, and/or bowel habit abnormalities in the absence of obvious anatomic or physiologic abnormalities on routine diagnostic tests. These symptoms are attributable to gastrointestinal sensorimotor dysfunctions resulting from peripheral and/or central mechanisms. Available drugs target the underlying bowel disturbance (i.e., constipation, diarrhea, or both), supplemented when necessary by management of pain. Osmotic and stimulant laxatives, secretagogues, and serotonin 5-HT4 receptor agonists are approved for treating constipation. Loperamide, anticholinergic agents, rifaximin, bile-acid binding agents, eluxadoline, and clonidine are used to treat diarrhea. Several exciting new compounds, some of which have been evaluated in humans, are currently under development.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29172123      PMCID: PMC5725238          DOI: 10.1016/j.coph.2017.10.015

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  55 in total

Review 1.  Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations.

Authors:  Brian E Lacy; Julie C Moreau
Journal:  J Am Assoc Nurse Pract       Date:  2016-07       Impact factor: 1.165

2.  Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function.

Authors:  Suwebatu T Odunsi-Shiyanbade; Michael Camilleri; Sanna McKinzie; Duane Burton; Paula Carlson; Irene A Busciglio; Jesse Lamsam; Ravinder Singh; Alan R Zinsmeister
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-30       Impact factor: 11.382

3.  Histamine H4 and H1 receptors contribute to postinflammatory visceral hypersensitivity.

Authors:  Annemie Deiteren; Joris G De Man; Nathalie E Ruyssers; Tom G Moreels; Paul A Pelckmans; Benedicte Y De Winter
Journal:  Gut       Date:  2014-02-21       Impact factor: 23.059

4.  Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome.

Authors:  C Cremon; V Stanghellini; M R Barbaro; R F Cogliandro; L Bellacosa; J Santos; M Vicario; M Pigrau; C Alonso Cotoner; B Lobo; F Azpiroz; S Bruley des Varannes; M Neunlist; D DeFilippis; T Iuvone; S Petrosino; V Di Marzo; G Barbara
Journal:  Aliment Pharmacol Ther       Date:  2017-02-06       Impact factor: 8.171

5.  Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome.

Authors:  M Camilleri; A Acosta; I Busciglio; A Boldingh; R B Dyer; A R Zinsmeister; A Lueke; A Gray; L J Donato
Journal:  Aliment Pharmacol Ther       Date:  2015-01-16       Impact factor: 8.171

6.  Role for protease activity in visceral pain in irritable bowel syndrome.

Authors:  Nicolas Cenac; Christopher N Andrews; Marinella Holzhausen; Kevin Chapman; Graeme Cottrell; Patricia Andrade-Gordon; Martin Steinhoff; Giovanni Barbara; Paul Beck; Nigel W Bunnett; Keith A Sharkey; Jose Geraldo P Ferraz; Eldon Shaffer; Nathalie Vergnolle
Journal:  J Clin Invest       Date:  2007-02-15       Impact factor: 14.808

7.  Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.

Authors:  Shin Fukudo; Yoshikazu Kinoshita; Toshikatsu Okumura; Motoko Ida; Hiraku Akiho; Yoshihiro Nakashima; Akito Nishida; Ken Haruma
Journal:  Gastroenterology       Date:  2015-11-06       Impact factor: 22.682

8.  A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.

Authors:  William D Chey; Michael Camilleri; Lin Chang; Leif Rikner; Hans Graffner
Journal:  Am J Gastroenterol       Date:  2011-05-24       Impact factor: 10.864

9.  Possible therapeutic role of IgE blockade in irritable bowel syndrome.

Authors:  Eli Magen; Tinatin Chikovani
Journal:  World J Gastroenterol       Date:  2016-11-21       Impact factor: 5.742

10.  Effect of prucalopride on symptoms of chronic constipation.

Authors:  J Tack; V Stanghellini; D Dubois; A Joseph; L Vandeplassche; R Kerstens
Journal:  Neurogastroenterol Motil       Date:  2013-09-20       Impact factor: 3.598

View more
  13 in total

1.  Lubiprostone is non-selective activator of cAMP-gated ion channels and Clc-2 has a minor role in its prosecretory effect in intestinal epithelial cells.

Authors:  Apurva A Oak; Tifany Chu; Pattareeya Yottasan; Parth D Chhetri; Jie Zhu; Justin Du Bois; Onur Cil
Journal:  Mol Pharmacol       Date:  2022-06-09       Impact factor: 4.054

Review 2.  Chronic Constipation.

Authors:  Adil E Bharucha; Arnold Wald
Journal:  Mayo Clin Proc       Date:  2019-05-01       Impact factor: 7.616

3.  4,8-Dimethylcoumarin Inhibitors of Intestinal Anion Exchanger slc26a3 (Downregulated in Adenoma) for Anti-Absorptive Therapy of Constipation.

Authors:  Sujin Lee; Onur Cil; Peter M Haggie; Alan S Verkman
Journal:  J Med Chem       Date:  2019-09-03       Impact factor: 7.446

4.  SLC26A3 inhibitor identified in small molecule screen blocks colonic fluid absorption and reduces constipation.

Authors:  Peter M Haggie; Onur Cil; Sujin Lee; Joseph-Anthony Tan; Amber A Rivera; Puay-Wah Phuan; Alan S Verkman
Journal:  JCI Insight       Date:  2018-07-26

5.  The economic burden of constipation therapy.

Authors:  Anamaria Albu; Andreea Farcas; Liliana David; Dan L Dumitrascu
Journal:  Med Pharm Rep       Date:  2019-07-31

6.  Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial.

Authors:  Chao Deng; Yanni Lou; Yu Gao; Bo Deng; Fei Su; Liqun Jia
Journal:  Trials       Date:  2020-05-01       Impact factor: 2.279

7.  Effect of electroacupuncture treatment on functional constipation in adults: A protocol for systematic review.

Authors:  Na Li; Ruihui Wang; Xia Ai; Xinrong Guo; Juan Liu; Dong Wang; Lei Sun; Rongchao Zhang
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

8.  Traditional East Asian herbal medicines for the treatment of poststroke constipation: A protocol for systematic review and meta analysis.

Authors:  Chul Jin; Bo-Hyoung Jang; Jin Pyeong Jeon; Ye-Seul Lee; Seung-Bo Yang; Seungwon Kwon
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

9.  Treatment of poststroke constipation with moxibustion: A case report.

Authors:  Junmao Wen; Zhenjie Zhuang; Minhong Zhao; Dongming Xie; Bo Xie; Lixing Zhuang; Zheng Liang; Wei Wu; Hongwei Xu
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

Review 10.  Recent advances in understanding and managing chronic constipation.

Authors:  David O Prichard; Adil E Bharucha
Journal:  F1000Res       Date:  2018-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.